Akso Health (AHG) Research & Development (2017 - 2019)

Akso Health (AHG) has reported Research & Development for 3 consecutive years, with $9.3 million the latest figure, recorded in Q3 2019.

• Quarterly Research & Development fell 21.14% year-over-year to $9.3 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was -$1.2 million (down 103.8% YoY) and the FY2024 annual result came in at $168421.0, up 2428.46% from the prior year.
• Research & Development advanced to $9.3 million in Q3 2019 per AHG's latest filing, from -$29.4 million in the prior quarter.
• Over the last five years, Research & Development for AHG reached as high as $11.7 million in Q3 2018 and fell as low as -$29.4 million in Q1 2019.
• A 3-year average of $2.9 million and a median of $5.5 million in 2017 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2018 — Research & Development jumped 354.15% — and 2019, when it tumbled 941.39%.
• Year by year, Research & Development stood at $5.5 million in 2017, then surged by 30.84% to $7.2 million in 2018, then grew by 29.13% to $9.3 million in 2019.
• According to Business Quant data, Research & Development over the past three periods registered $9.3 million, -$29.4 million, and $7.2 million for Q3 2019, Q1 2019, and Q4 2018 respectively.